Pfizer’s Africa Vaccine Deal Raises Questions on Ip Waiver Plan

Opponents of an IP waiver say it would compromise critical aspects of production, leaving partnerships with vaccine makers a better option for getting doses out the door.

“This is the type of thing that opponents of the waiver have been calling for,” said Jaci McDole, a senior policy analyst at the Information Technology and Innovation Foundation. Partnerships are how companies “get these vaccines and therapeutics to the people that need them” while “making sure they maintain quality control through the supply chain.”